NA-931 10mg

Description

Disclaimer: All Iron Mountain Labz products are only intended for laboratory research use and are not approved for use outside of controlled research settings. All referenced research was conducted under IRB/IACUC/AWA-compliant protocols. This compound is not approved for human or veterinary use.

Overview of NA-931 10mg

NA-931 is a first-in-class orally active synthetic cyclic peptide derived from a cyclic fragment of insulin-like growth factor 1 (IGF-1)  

It has been classified in preclinical research settings as a quadruple receptor agonist — a compound engineered to simultaneously engage four distinct metabolic hormone receptor systems. These receptors are 

• Insulin-like growth factor 1 receptor (IGF-1R) 
• Glucagon-like peptide-1 receptor (GLP-1R), 
• Glucose-dependent insulinotropic polypeptide receptor (GIPR), 
• Glucagon receptor (GCGR).

NA-931 is studied in preclinical research settings for its interaction with incretin signaling networks, IGF-1 anabolic receptor pathways, glucagon-mediated hepatic energy expenditure cascades, and hypothalamic appetite regulation circuits. Investigational research has explored its role in metabolic receptor co-activation, body composition modulation, and glycemic signaling regulation in controlled laboratory environments.

Why Buy NA-931 10mg from Iron Mountain Labz?

Researchers prefer Iron Mountain Labz for buying NA-931 10mg due to the following reasons:

At Iron Mountain Labz, NA-931 10mg is tested with HPLC and confirmed at ≥99%+ purity. The assay result of this product meets research-grade standards for investigational use. A Certificate of Analysis (COA) is also provided for verification.

Frequently Asked Questions

What distinguishes NA-931 from single or dual receptor agonists in research models? 

NA-931 (Bioglutide) is a first-in-class small synthetic molecule derived from a cyclic IGF-1 fragment, characterized in preclinical research as a quadruple receptor agonist targeting IGF-1R, GLP-1R, GIPR, and GCGR simultaneously. Unlike single-receptor agonists such as GLP-1R-targeting compounds or dual agonists targeting GLP-1R and GIPR, NA-931’s investigational profile encompasses four complementary metabolic receptor pathways in a single compound. Preclinical findings suggest this multi-receptor engagement distributes signaling activity across parallel biological systems, offering a broader investigational model for studying integrated metabolic receptor co-activation dynamics.

How does NA-931 interact with its four target receptor systems at the molecular level? 

Preclinical in vitro assay data indicate that NA-931 functions as a potent agonist at nanomolar concentrations across all four target receptor systems. GLP-1R and GIPR engagement has been associated with cAMP-dependent signaling cascades in receptor-expressing cell lines, consistent with incretin pathway activation dynamics. GCGR agonism in research models has been linked to hepatic cAMP production and downstream lipid oxidation signaling. IGF-1R activation has been associated with Akt phosphorylation cascades in IGF-1R-expressing preclinical cell systems, a pathway investigated in the context of anabolic signaling and lean mass preservation in metabolic research models.

What are the observed effects of NA-931 in experimental and investigational settings? 

Preclinical and early-phase investigational data associate NA-931 with dose-dependent modulation of body weight parameters in research models, attenuation of hepatic lipid accumulation signaling, regulation of glucose-stimulated insulin secretion cascades, and preservation of lean mass markers in conjunction with energy expenditure modulation. In vitro findings confirm receptor activation across all four target systems. Investigational research has also begun exploring NA-931’s potential interaction with alcohol use disorder-related behavioral pathways in preclinical models.

What are the noted adverse variables of NA-931 in research settings? 

Comprehensive long-term preclinical data on NA-931 remain limited, and further systematic investigation is required to fully characterize its adverse variable profile across extended exposure protocols. Observations from investigational settings note potential variability in GCGR-associated hepatic signaling dynamics under elevated concentration conditions, possible modulation of GLP-1R desensitization kinetics with sustained compound exposure, and concentration-dependent off-target receptor interactions requiring further characterization in preclinical models. Researchers are advised to establish appropriate concentration ranges within their specific experimental frameworks before initiating investigational protocols.

Where to buy NA-931 10mg online?

NA-931 10mg is available for purchase at the Iron Mountain Labz online store. Each product is held to strict purity standards and comes with a Certificate of Analysis (COA) for complete research verification.

Note on the data table: The CAS number, molecular formula, and molar mass for NA-931 have not been publicly disclosed by the developer (Biomed Industries, Inc.) at this time. Rather than listing unverified values, those fields have been marked accordingly.